Acorda Therapeutics, Inc. (Acorda) is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company’s Ampyra (dalfampridine) is used as a treatment to improve walking in patients with MS. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride. The Company is developing six clinical-stage therapies and one pre-clinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. It is also developing Plumiaz (trade name for Diazepam Nasal Spray), a nasal spray formulation of diazepam, for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.